These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28762051)

  • 1. Can premium differentiation counteract adverse selection in the Dutch supplementary health insurance? A simulation study.
    van Winssen KPM; van Kleef RC; van de Ven WPMM
    Eur J Health Econ; 2018 Jun; 19(5):757-768. PubMed ID: 28762051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Supplementary insurance as a switching cost for basic health insurance: Empirical results from the Netherlands.
    Willemse-Duijmelinck DMID; van de Ven WPMM; Mosca I
    Health Policy; 2017 Oct; 121(10):1085-1092. PubMed ID: 28855064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A voluntary deductible in health insurance: the more years you opt for it, the lower your premium?
    van Winssen KP; van Kleef RC; van de Ven WP
    Eur J Health Econ; 2017 Mar; 18(2):209-226. PubMed ID: 26857921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How profitable is a voluntary deductible in health insurance for the consumer?
    van Winssen KP; van Kleef RC; van de Ven WP
    Health Policy; 2015 May; 119(5):688-95. PubMed ID: 25747511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection Incentives for Health Insurers in the Presence of Sophisticated Risk Adjustment.
    van Kleef RC; Eijkenaar F; van Vliet RCJA
    Med Care Res Rev; 2020 Dec; 77(6):584-595. PubMed ID: 30704337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing behaviour of nonprofit insurers in a weakly competitive social health insurance market.
    Douven RC; Schut FT
    J Health Econ; 2011 Mar; 30(2):439-49. PubMed ID: 21295365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse selection with a multiple choice among health insurance plans: a simulation analysis.
    Marquis MS
    J Health Econ; 1992 Aug; 11(2):129-51. PubMed ID: 10122975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Adjustment, Reinsurance Improved Financial Outcomes For Individual Market Insurers With The Highest Claims.
    Jacobs PD; Cohen ML; Keenan P
    Health Aff (Millwood); 2017 Apr; 36(4):755-763. PubMed ID: 28356320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supplementary health insurance as a tool for risk-selection in mandatory basic health insurance markets.
    Paolucci F; Schut E; Beck K; Gress S; Van de Voorde C; Zmora I
    Health Econ Policy Law; 2007 Apr; 2(Pt 2):173-92. PubMed ID: 18634661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence.
    van de Ven WP; van Vliet RC; van Kleef RC
    Eur J Health Econ; 2017 Mar; 18(2):167-180. PubMed ID: 26837411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model to decompose the performance of supplementary private health insurance markets.
    Leidl R
    Int J Health Care Finance Econ; 2008 Sep; 8(3):193-208. PubMed ID: 18568435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spillover effects of supplementary on basic health insurance: evidence from The Netherlands.
    Roos AF; Schut FT
    Eur J Health Econ; 2012 Feb; 13(1):51-62. PubMed ID: 20862510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to coverage for high-risks in a competitive individual health insurance market: via premium rate restrictions or risk-adjusted premium subsidies?
    van de Ven WP; van Vliet RC; Schut FT; van Barneveld EM
    J Health Econ; 2000 May; 19(3):311-39. PubMed ID: 10977194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs, commitment and locality: a comparison of for-profit and not-for-profit health plans.
    Inquiry; 2004; 41(2):116-29. PubMed ID: 15449428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk adjusted premium subsidies and risk sharing: key elements of the competitive sickness fund market in the Netherlands.
    Lamers LM; van Vliet RC; van de Ven WP
    Health Policy; 2003 Jul; 65(1):49-62. PubMed ID: 12818745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Citizen engagement in healthcare procurement decision-making by healthcare insurers: recent experiences in the Netherlands.
    Brito Fernandes Ó; Bos V; Klazinga N; Kringos D
    Health Res Policy Syst; 2022 Dec; 20(1):137. PubMed ID: 36550520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of adverse selection in Iranian supplementary health insurance market.
    Mahdavi G; Izadi Z
    Iran J Public Health; 2012; 41(7):44-52. PubMed ID: 23113209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk selection in a regulated health insurance market: a review of the concept, possibilities and effects.
    van Kleef RC; van de Ven WP; van Vliet RC
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):743-52. PubMed ID: 24219050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should administrative costs in health insurance be included in the risk-equalization? An analysis of five countries.
    Douven R; Kauer L; Demme S; Paolucci F; van de Ven W; Wasem J; Zhao X
    Eur J Health Econ; 2022 Dec; 23(9):1437-1453. PubMed ID: 35129731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do insurers respond to risk adjustment? A long-term, nationwide analysis from Switzerland.
    von Wyl V; Beck K
    Eur J Health Econ; 2016 Mar; 17(2):171-83. PubMed ID: 25663430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.